SCHEMBL8667871

SCHEMBL8667871

C=CCOC(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.60
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ACE P12821 10/20 0.45
REN P00797 3/20 0.43
LMNA P02545 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CYP2C19 P33261 1/20 0.43
KDM4E B2RXH2 1/20 0.43
F2 P00734 1/20 0.43
LTA4H P09960 1/20 0.43
MAPT P10636 1/20 0.43
PEPD P12955 1/20 0.43
ALOX15 P16050 1/20 0.43
PTGS1 P23219 1/20 0.43
HTR2A P28223 1/20 0.43
PTGS2 P35354 1/20 0.43
HRH1 P35367 1/20 0.43
THPO P40225 1/20 0.43
PMP22 Q01453 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10683300 1.00 RAB9A (0.60) RAB9AALDH1A1SMN1; SMN2ACEREN
SCHEMBL8667874 1.00 RAB9A (0.60) RAB9AALDH1A1SMN1; SMN2ACEREN
SCHEMBL7173020 0.95 RAB9A (0.55) RAB9AALDH1A1SMN1; SMN2ACEREN
SCHEMBL9193401 0.95 RAB9A (0.55) RAB9AALDH1A1SMN1; SMN2ACEREN
SCHEMBL5702004 0.90 RAB9A (0.48) RAB9AALDH1A1SMN1; SMN2ACEREN
SCHEMBL7877679 0.90 RAB9A (0.48) RAB9AALDH1A1SMN1; SMN2ACEREN
SCHEMBL5702051 0.90 RAB9A (0.48) RAB9AALDH1A1SMN1; SMN2ACEREN
Proline SCHEMBL8027265 0.87 RAB9A (0.48) RAB9AALDH1A1SMN1; SMN2ACEREN
SCHEMBL9385519 0.86 RAB9A (0.48) RAB9AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL14908297 0.86 RAB9A (0.44) RAB9AALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115053184-B Composition for forming EUV resist underlayer film 日产化学株式会社 2024-12-06 CN disclosed
CN-115053184-A Composition for forming EUV resist underlayer film 日产化学株式会社 2022-09-13 CN disclosed
US-20190135862-A1 NDMA RECEPTOR MODULATORS AND USES THEREOF INNOVIVA TRC HOLDINGS LLC 2019-05-09 US disclosed
EP-2771021-B1 NMDA RECEPTOR MODULATORS AND USES THEREOF NORTH WESTERN UNIV (US) 2018-08-29 EP disclosed
WO-2016090305-A1 SOLID-PHASE SYNTHESIS OF PEPTIDES CONTAINING BULKY DEHYDROAMINO ACIDS CASTLE STEVEN L (US) 2016-06-09 WO disclosed
US-20150051262-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF NORTHWESTERN UNIVERSITY (US) 2015-02-19 US disclosed
US-20150051262-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF NORTHWESTERN UNIVERSITY (US) 2015-02-19 US disclosed
WO-2013063120-A2 NMDA RECEPTOR MODULATORS AND USES THEREOF NORTHWESTERN UNIVERSITY (US) 2013-05-02 WO disclosed
US-5847117-A Reagent and catalytic process useful for cleaving a protected functional group RHONE-POULENC CHIMIE (FR) 1998-12-08 US disclosed
EP-0330108-B1 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO (JP) 1995-12-27 EP disclosed
EP-0394991-B1 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO (JP) 1994-08-17 EP disclosed
US-5102877-A Carbapenicillin antibiotics FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-04-07 US disclosed
US-5081237-A Chemical intermediates for bactericides FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1992-01-14 US disclosed
EP-0394991-A1 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-10-31 EP disclosed
US-4923857-A CARBAPENICILLINS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-08 US disclosed
EP-0330108-A1 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-08-30 EP disclosed
EP-0233155-A1 Aminoacyloxymethyl compounds CIBA-GEIGY AG (CH) 1987-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135862-A1 NDMA RECEPTOR MODULATORS AND USES THEREOF OPRL1, GRIN2A, GRM1 RAB9A 1054/4885ALDH1A1 3341/4885SMN1; SMN2 123/4885
US-20150051262-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A RAB9A 2220/4885ALDH1A1 3800/4885SMN1; SMN2 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.